Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.14 USD | -7.01% | -5.52% | -25.41% |
Financials (USD)
Sales 2024 * | 31.99M | Sales 2025 * | 3.01M | Capitalization | 851M |
---|---|---|---|---|---|
Net income 2024 * | -197M | Net income 2025 * | -306M | EV / Sales 2024 * | 10.1 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 164 x |
P/E ratio 2024 * |
-4.37
x | P/E ratio 2025 * |
-3.22
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.28% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | -5.38% | ||
1 week | -5.27% | ||
Current month | +2.44% | ||
1 month | -9.86% | ||
3 months | -16.94% | ||
6 months | +4.42% | ||
Current year | -25.21% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% | ||
0.04% | 1,487 M€ | +9.02% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 11.3 | -5.68% | 91 667 |
24-05-22 | 11.98 | +3.45% | 504,511 |
24-05-21 | 11.58 | -1.78% | 417,548 |
24-05-20 | 11.79 | -2.32% | 430,070 |
24-05-17 | 12.07 | +0.92% | 493,174 |
Delayed Quote Nasdaq, May 23, 2024 at 10:22 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.21% | 851M | |
+10.63% | 115B | |
+12.26% | 106B | |
-5.59% | 24.69B | |
-1.60% | 21.97B | |
-5.24% | 19.27B | |
-11.04% | 17.56B | |
-39.36% | 17.32B | |
+5.91% | 14.03B | |
+33.49% | 12.13B |
- Stock Market
- Equities
- ZNTL Stock